|
Patent landscape, scope, and claims: |
United States Patent 10,016,504: Scope, Claims, and Landscape Analysis
What is the core innovation protected by US Patent 10,016,504?
United States Patent 10,016,504, granted on July 10, 2018, to Bristol-Myers Squibb Company, protects a method of treating a patient with a PD-1-mediated condition using an anti-PD-1 antibody. The method involves administering a therapeutically effective amount of an anti-PD-1 antibody to a patient diagnosed with or at risk of developing a PD-1-mediated condition. The patent defines the anti-PD-1 antibody as having specific characteristics, including binding to human PD-1 with a dissociation equilibrium constant (KD) of 10 nanomolar (nM) or less and having a half-life in cynomolgus monkeys of at least 10 days. The patent also specifies certain amino acid sequences for the antibody's complementarity-determining regions (CDRs). The PD-1-mediated conditions are broadly defined to include cancer and infectious diseases [1].
What are the key claims of the patent?
The patent contains multiple claims, with Claim 1 serving as the foundational independent claim. The claims can be categorized as follows:
Method of Treatment Claims:
- Claim 1: This is the primary method of treatment claim. It covers a method for treating a patient with a PD-1-mediated condition. The method involves administering a therapeutically effective amount of an anti-PD-1 antibody. Key defining features of the antibody include its binding affinity to human PD-1 (KD ≤ 10 nM) and its pharmacokinetic profile in cynomolgus monkeys (half-life ≥ 10 days).
- Claim 2: Dependent on Claim 1, this claim further specifies that the anti-PD-1 antibody is a humanized antibody.
- Claim 3: Dependent on Claim 1, this claim specifies that the anti-PD-1 antibody is a human antibody.
- Claim 4: Dependent on Claim 1, this claim defines the antibody as comprising specific heavy and light chain variable region amino acid sequences, or CDRs, as set forth in the patent.
- Claim 5: Dependent on Claim 1, this claim specifies that the PD-1-mediated condition is cancer.
- Claim 6: Dependent on Claim 5, this claim lists specific types of cancer, including but not limited to melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, bladder cancer, and colorectal cancer.
- Claim 7: Dependent on Claim 5, this claim specifies that the cancer is a solid tumor.
- Claim 8: Dependent on Claim 1, this claim specifies that the PD-1-mediated condition is an infectious disease.
- Claim 9: Dependent on Claim 8, this claim lists specific types of infectious diseases, including but not limited to HIV, hepatitis B, and hepatitis C.
Antibody Claims:
- Claim 10: This independent claim covers an anti-PD-1 antibody characterized by its binding affinity to human PD-1 (KD ≤ 10 nM) and its half-life in cynomolgus monkeys (≥ 10 days).
- Claim 11: Dependent on Claim 10, this claim specifies that the antibody is a humanized antibody.
- Claim 12: Dependent on Claim 10, this claim specifies that the antibody is a human antibody.
- Claim 13: Dependent on Claim 10, this claim specifies that the antibody comprises specific heavy and light chain variable region amino acid sequences, or CDRs, as set forth in the patent.
- Claim 14: Dependent on Claim 10, this claim describes the antibody further by reference to specific figures within the patent document, which illustrate particular CDR sequences.
Formulation Claims:
- Claim 15: This independent claim covers a pharmaceutical composition comprising an anti-PD-1 antibody as defined in Claim 10 and a pharmaceutically acceptable carrier.
- Claim 16: Dependent on Claim 15, this claim specifies that the pharmaceutical composition further comprises one or more additional therapeutic agents.
- Claim 17: Dependent on Claim 16, this claim lists examples of additional therapeutic agents, such as chemotherapy agents, other antibodies, or cytokines.
Summary of Claim Scope:
The patent broadly claims methods of treating PD-1-mediated conditions using an anti-PD-1 antibody with specific in vitro binding and in vivo pharmacokinetic properties. It also claims the antibody itself and pharmaceutical compositions containing it. The claims are drafted to encompass a range of PD-1-mediated conditions, particularly cancers, and allow for co-administration with other therapies. The specific antibody sequence information provided in some dependent claims further narrows the scope for those particular embodiments.
What is the asserted therapeutic target and mechanism of action?
The asserted therapeutic target is Programmed Cell Death protein 1 (PD-1). PD-1 is an inhibitory receptor expressed on the surface of activated T cells, B cells, and myeloid cells. Its primary function is to regulate the immune response and prevent autoimmune diseases by dampening T cell activity [2].
The mechanism of action involves blocking the interaction between PD-1 and its ligands, Programmed Death-Ligand 1 (PD-L1) and Programmed Death-Ligand 2 (PD-L2). These ligands are often expressed by tumor cells and can induce T cell exhaustion, allowing the tumor to evade immune surveillance. By binding to PD-1, the anti-PD-1 antibody prevents PD-1 from interacting with its ligands, thereby releasing the brake on the immune system. This restoration of T cell function allows T cells to recognize and attack cancer cells. The patent defines the specific antibody by its binding affinity (KD ≤ 10 nM) to human PD-1 and its pharmacokinetic half-life in cynomolgus monkeys (≥ 10 days), suggesting a focus on antibodies with high potency and sustained systemic exposure for effective immune modulation in PD-1-mediated conditions [1].
What is the patent's landscape for similar technologies and competitors?
The patent landscape for anti-PD-1 antibodies is highly competitive and crowded, characterized by extensive patent filings from multiple pharmaceutical companies and research institutions. Bristol-Myers Squibb's patent 10,016,504 is part of this broader ecosystem protecting immunotherapies targeting the PD-1/PD-L1 pathway.
Key Competitors and Their Patents:
- Merck & Co. (Keytruda®): Merck holds foundational patents for pembrolizumab, including U.S. Patent 8,779,105, which covers antibodies that bind to PD-1. Their patent portfolio is extensive, covering various aspects of pembrolizumab's use and composition.
- Roche (Tecentriq®): While Tecentriq® is an anti-PD-L1 antibody, Roche also has a significant presence in the immuno-oncology space and has patents related to PD-1 pathway modulation.
- AstraZeneca (Imfinzi®): AstraZeneca's durvalumab is an anti-PD-L1 antibody. Similar to Roche, their patent strategy involves protecting various aspects of PD-1 pathway inhibition.
- Nivolumab (Opdivo®): Opdivo®, developed by Bristol-Myers Squibb, is the primary drug associated with the innovation protected by U.S. Patent 10,016,504. Bristol-Myers Squibb has a robust portfolio of patents covering nivolumab, its manufacturing, formulations, and therapeutic uses. Patent 10,016,504 specifically addresses certain characteristics of the anti-PD-1 antibody and its use in treating PD-1-mediated conditions.
Patenting Strategies:
Companies in this space employ multi-pronged patenting strategies:
- Composition of Matter Claims: These are the strongest claims, protecting the antibody molecule itself. U.S. Patent 10,016,504 includes such claims (Claim 10).
- Method of Treatment Claims: These claims protect specific uses of the antibody for treating particular diseases or patient populations. U.S. Patent 10,016,504 has numerous method of treatment claims (Claims 1-9).
- Formulation Claims: These protect specific drug formulations, which can extend market exclusivity after core composition patents expire. U.S. Patent 10,016,504 includes formulation claims (Claims 15-17).
- Manufacturing Process Claims: Patents can cover novel or efficient methods of producing the antibody.
- Biomarker Claims: Patents may claim methods of using specific biomarkers to identify patients most likely to respond to treatment.
Potential for Litigation and Licensing:
The crowded patent landscape increases the likelihood of patent disputes and litigation. Companies may assert their patents against competitors, leading to challenges regarding inventorship, enablement, written description, and obviousness. Licensing agreements are also common, allowing companies to gain access to patented technology or resolve disputes. U.S. Patent 10,016,504, with its specific antibody characteristics and method of treatment claims, is a key asset for Bristol-Myers Squibb in its ongoing efforts to protect its market share for nivolumab and its associated intellectual property. The defined binding affinity and half-life parameters are crucial for distinguishing its protected antibody from potentially similar molecules developed by competitors.
What is the patent's expiration timeline?
Patent 10,016,504 has a standard term for utility patents in the United States, which is generally 20 years from the filing date, subject to maintenance fees.
- Filing Date: August 18, 2017 [1].
- Issue Date: July 10, 2018 [1].
- Expiration Date: Assuming no extensions or adjustments, the patent is set to expire 20 years from the filing date, which would be August 18, 2037.
It is important to note that patent terms can be affected by several factors:
- Patent Term Adjustment (PTA): This can extend the patent term if there were delays in prosecution by the USPTO.
- Patent Term Extension (PTE): For pharmaceutical patents, PTE can compensate for regulatory review periods (e.g., FDA approval). Nivolumab (Opdivo®) has undergone regulatory review, which could qualify for PTE, potentially extending the effective market exclusivity beyond the standard expiration date. The specific duration of PTE depends on the length of the regulatory review period.
- Maintenance Fees: Failure to pay required maintenance fees to the USPTO can lead to the patent lapsing prematurely.
Companies actively monitor these timelines to plan for market entry of generic or biosimilar versions of the protected drug.
What are the key commercial implications of this patent?
The commercial implications of U.S. Patent 10,016,504 are significant for Bristol-Myers Squibb (BMS) and the broader immuno-oncology market.
- Market Exclusivity for Nivolumab (Opdivo®): This patent contributes to BMS's intellectual property protection for nivolumab. The claims related to the specific characteristics of the anti-PD-1 antibody, such as its binding affinity and half-life, and its use in treating PD-1-mediated conditions, are critical for defending against biosimilar or generic competition. As nivolumab is a blockbuster drug, maintaining exclusivity is paramount.
- Protection of Combination Therapies: Claims 16 and 17, which cover pharmaceutical compositions comprising the anti-PD-1 antibody along with additional therapeutic agents, are vital for protecting BMS's strategies involving combination therapies. These combinations, particularly with agents like ipilimumab (Yervoy®), are key drivers of Opdivo® sales and clinical utility.
- Barrier to Entry for Competitors: The patent establishes a clear legal barrier for other companies seeking to market an anti-PD-1 antibody with substantially similar properties or therapeutic applications. Competitors developing their own anti-PD-1 antibodies must navigate this patent to avoid infringement. This could necessitate developing antibodies with significantly different amino acid sequences, binding characteristics, or pharmacokinetic profiles, or seeking licenses.
- Licensing Opportunities and Litigation Risk: The patent serves as a valuable asset for potential licensing negotiations. Conversely, it also represents a potential point of contention in patent litigation. Competitors may challenge the patent's validity or argue that their product does not infringe.
- Valuation and Investment Decisions: For investors and R&D decision-makers, understanding the scope and expiration timeline of this patent is crucial for assessing the long-term commercial viability of nivolumab and its therapeutic class. It informs investment in direct competitors, biosimilar development, or alternative therapeutic pathways.
- Therapeutic Standard Setting: The defined parameters for the anti-PD-1 antibody (KD ≤ 10 nM, half-life ≥ 10 days in cynomolgus monkeys) can be seen as setting a benchmark for the performance characteristics of an effective anti-PD-1 therapeutic, influencing the development goals of other research programs.
The patent's expiration in 2037, potentially extended by PTE, provides a substantial period of market exclusivity for BMS, allowing them to maximize the commercial return on their R&D investment in nivolumab.
Key Takeaways
- US Patent 10,016,504 protects methods of treating PD-1-mediated conditions using an anti-PD-1 antibody with specific binding affinity (KD ≤ 10 nM) and pharmacokinetic properties (half-life ≥ 10 days in cynomolgus monkeys).
- The patent's claims encompass the antibody composition, pharmaceutical formulations, and treatment methods for various cancers and infectious diseases.
- The patent is held by Bristol-Myers Squibb Company and is foundational to their nivolumab (Opdivo®) franchise.
- The patent is set to expire in August 2037, with potential extensions through Patent Term Extension (PTE) due to regulatory review periods.
- The competitive landscape for anti-PD-1 antibodies is intense, with multiple players holding significant patent portfolios, leading to potential licensing and litigation activities.
- The patent's scope provides significant market exclusivity for BMS, impacting competitor strategies, investment decisions, and the development of biosimil or generic alternatives.
FAQs
- What specific anti-PD-1 antibody is primarily protected by this patent?
While the patent claims a class of anti-PD-1 antibodies meeting specific criteria, it is strongly associated with nivolumab (Opdivo®), marketed by Bristol-Myers Squibb.
- Can competitors develop their own anti-PD-1 antibodies if they have different binding affinities or half-lives?
Yes, competitors can develop anti-PD-1 antibodies that fall outside the specific claims of this patent by differing in binding affinity, pharmacokinetic profile, or amino acid sequence, provided they do not infringe on other valid patents.
- Does this patent cover combination therapies?
Yes, Claims 16 and 17 specifically cover pharmaceutical compositions that include the anti-PD-1 antibody along with one or more additional therapeutic agents.
- What is the significance of the cynomolgus monkey half-life requirement?
This specification serves as a pharmacokinetic benchmark in a relevant non-human primate model, indicating a desirable duration of drug presence in the body for sustained therapeutic effect, thereby differentiating the protected antibody.
- Will generics or biosimil versions of nivolumab be available immediately after the patent expires in 2037?
The expiration of this patent in 2037 is a significant factor, but the actual market entry of biosimil versions will also depend on the expiration of other relevant patents, any granted Patent Term Extensions (PTE), and the lengthy regulatory approval process for biosimil products.
Citations
[1] Bristol-Myers Squibb Company, assignee. (2018). Anti-PD-1 antibody, antibody composition and method of treatment (U.S. Patent No. 10,016,504). United States Patent Office.
[2] Pardoll, D. M. (2012). Cancer therapy with antibodies targeting immune checkpoints. Nature Reviews Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3238
More… ↓
⤷ Start Trial
|
